COMMUNIQUÉS West-GlobeNewswire
 
      -   
  IPSEN - Buy-back programme - Art 5 of MAR - Week 42 - 202521/10/2025
-   
  Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million21/10/2025
-   
  Glo & Spa-rkle Aesthetics and Medspa Celebrates 700-Plus 5-Star Google Reviews, Cementing Rank as Best Laser Tattoo Removal Medspa in Lubbock, Texas.21/10/2025
-   
  beyond|AESTHETICS Owner Leslie Petersen, NP, Accepted into Elite Dr. Mauricio de Maio MD Codes™ Fellowship Program21/10/2025
-   
  Quercis Pharma and The Galien Foundation to Spotlight Sickle Cell Disease at the 2025 Patient Summit21/10/2025
-   
  Glucose Health, Inc. (OTC: GLUC) Announces New Management Appointments and Strategic Outlook21/10/2025
-   
  Solenic Medical Announces Successful Use of Its AMF Technology Under FDA Compassionate Use Authorization21/10/2025
-   
  AskBio Announces Publication in Nature Medicine of 12-month data from Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure21/10/2025
-   
  Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 202521/10/2025
-   
  Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 202521/10/2025
-   
  Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week21/10/2025
-   
  Medical Specialists of the Palm Beaches Unveils State-of-the-Art Medical Facility in Wellington, Florida21/10/2025
-   
  Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET21/10/2025
-   
  Avalyn Announces Multiple Presentations at the Pulmonary Fibrosis Foundation (PFF) Summit 202521/10/2025
-   
  Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 202521/10/2025
-   
  InnovAge to Announce Fiscal First Quarter 2026 Financial Results and Host Conference Call Tuesday, November 4, 202521/10/2025
-   
  Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit21/10/2025
-   
  Notice convening an Extraordinary General Meeting of Novo Nordisk A/S21/10/2025
-   
  Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.21/10/2025
Pages